Biogen’s $900 million settlement signals scrutiny on speaker fees
Pharmaceutical Technology
OCTOBER 5, 2022
However, new MS drugs like Novartis ’ Gilenya, were going to soon enter the market and increase competition within the MS therapeutic landscape. Ferry explains, “The government deems that [special fraud alert] as public notice to the industry that they are concerned about these public programs.”.
Let's personalize your content